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Photodynamic therapy (PDT) utilizing Photofrin is proving to be effective for the treatment of early
stage lung cancer. However, wider clinical applications of Photofrin as a photosensitizer for various
cancers are hampered by potentially serious and prolonged skin photosensitivity. To prevent these
side effects and reduce the hospitalization period, we recently gave reduced doses of Photofrin by
bronchial arterial infusion. Five patients with endoscopically evaluated minimally invasive carci-
noma of the lung were given 0.7 mg/kg of Photofrin by bronchial arterial infusion 48 hr before PDT.
Complete remission was obtained in all 5 cases and no case showed skin photosensitivity when ex-
posed to sunlight under careful surveillance at one week after PDT.
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INTRODUCTION
Photodynamic therapy (PDT) using hematoporphyrin de-
rivative as aneffectivemodality in themanagementofcan-
cer is currentlyreceivingconsiderable attention (1-3). The
photosensitizer preparation most commonly used is a
complex mixture of porphyfins termed hematoporphyrin
derivative (HpD) or Photofrin, a partially purified prepa-
ration of HpD, which received government approval on
October 1994 in Japan. In spite ofexcellent results in clin-
ical studies, especially in early-stage lung cancer, wider
clinical applications ofPDT using HpD are hampered by
the skin photosensitivity it induces (4,5). Photofrin has
routinely been given intravenously at a dosage of 2.0
mg/kg body weight since the report of Dougherty et al.
(6); however, patients receiving Photofrin must avoid sun-
light for a minimum of 30 days to avoid sunburn (4).
On the other hand, regional infusion of anticancer
agents into the malignant lesion via a transarterial route
could minimize fast deactivation while increasing the an-
ticancer effect (7). Bronchial artery infusion (BAI) is
known to achieve high concentrations of anticancer drug
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in lung cancer tissue (8). To reduce skin photosensitivity
and to increase local photodynamic effects, a clinical
study oflow-dose Photofrin givenbyBAIwas performed.
MATERIALS AND METHODS
Patient Selection
The patients and their histories are outlined in Table 1.
Five patients with endoscopically evaluated early-stage
carcinoma of the lung and two with advanced carcinoma
were treated. Histologically, all cases were squamous cell
carcinoma. All 7 patients were men with a mean age of
73 years (range 60 to 81 years).
Procedure
The photosensitizerusedwas porfimersodium (Photofrin,
Ledede Japan Inc., Tokyo, Japan). One or more arteries
feeding the tumorwere identified angiographically before
infusion of Photofrin. After catheterization of the target
artery, a single dose ofPhotofrin (0.7 mg/kg body weight)
was slowly infused into the bronchial artery followed by
endoscopic PDT performed with topical anesthesia ap-
proximately 48 hr later. The new laser light delivery sys-
tem consists ofan excimer laser, which emits a pulse laser
beam coupled to a dye laser (Hamamatsu Photonics Ltd,204 T. OKUNAKA et al.
Table I Results ofBAI-PDT
Age Location of
Patient (yr) Sex Tumor
Histologic Skin Photo-
Type* Stage Result sensitivity
81 M Right B orifice
2 77 M Left B
3 77 M Right B orifice
4 70 M Left B
5 60 M Right main bronchus
6 79 M Left 2nd cadna
7 68 M Carina
*Sq, squamous cell carcinoma.
Sq (TINOM0) CR (-)
Sq (T2NOM0) CR (-)
Sq (T1NOM0) CR (-)
Sq (TINOM0) CR Grade
Sq (T2NOM0) CR (-)
Sq IIIA (T2N2M0) PR (-)
Sq IV (T4N2M 1) PR (-)
Hamamatsu, Japan) (9). The excimer laser uses a gas mix-
ture containing 0.9% Xe, 0.1% HC1, and 99% helium at 2
atm pressure. The optimal performance of this laser is ob-
tained at30 rnJ/pulse with one-halfpeakpowerx 10.9 nsec
at 308 nm. The XeC1 excimer laser (308 nm) can be cou-
pled to a pump system, which contains 2 M Rhodamine
B dye in ethanol to convert thebeam to630nm. Thebeams
from the excimer-dye lasers were focused onto 400 I.tm
fused silica fibers (Moritex Ltd, Nagoya, Japan), the tips
of which were fitted with microlens to improve the ho-
mogeneity of light distribution throughout the treatment
field. The final circular area of illumination was 1 cm2.
Illumination times ranged from 10-40 mins, giving en-
ergy densities of 100 to 200 J/cm2.
The tumor response to PDT was evaluated endoscopi-
cally, roentgenographically, cytologically, and histologi-
cally 1 month after treatment. Tumor response was
classified into three categories: complete remission (CR),
partial remission (PR), and no change (NC). CR was de-
fined as the complete absence oftumor endoscopically as
well as both cytologically and histologically. PR was de-
fined as a 50% or more reduction in tumor volume esti-
mated macroscopically or histologically, and NC was
defined as a reduction in tumor volume of less than 50%.
Skin photosensitivity was tested within 72 hr after
Photofrin administration (10). Testing was done on the
lower back. Test rectangles 1.5 by 2.5 cm were exposed
to visible light (400 to 750 nm) to cover the entire visible
absorption spectrum of Photofrin. The light source for
testing was a 500W projector lamp with a filter to remove
infrared light. The test light power density was 30 J/cm2.
Skin reactionwas evaluated24hr afterlightexposure. This
was graded as 0, 1+, 2+, or 3+. Grade 0 was defined as a
normal skin without any skin reaction; a 1+ reaction indi-
cated minimum erythema and/or mild redness. Moderate
redness with edema but no blistering or necrosis was rep-
resented by 2+. A 3+ reaction indicated redness, edema,
and blistering. Patients with no skin reaction to skin pho-
tosensitivity tests, were allowed to be exposed to sunlight
under careful surveillance at 1 week after PDT (10).
RESULTS
Table 1 shows the summary of results of BAI-PDT.
Complete remission was obtained in all five patients with
early-stage lung cancers, and partial remission was ob-
tained in the two patients with advanced disease. Only one
patient, (patient 4) showed mild, grade 1 photosensitivity.
Therewasnoevidence ofskin photosensitivity in the other
six patients.
Case Report
In this 81-year-old man (patient 1), lung cancer was ini-
tially diagnosed based on positive sputum cytologic find-
ings during a mass screening program for individuals at
risk for lung cancer. All roentgenographic examinations
were negative. The tumor was nodular, 5 by 5 mm in size
and located in the rightB6 (Fig. 1A). Itwas treatedby BAI-
PDT using an excimer-dye laser at 100 J/cm2. The tumor
disappeared completely and aCR was obtained (Fig. 1B).
Now, he is apparently disease-free 18 months after BAI-
PDT. Skin photosensitivity test revealed grade 1 skin pho-
tosensitivity. No other side effects were recognized.
DISCUSSION
More than 3000 patients with a wide variety of malig-
nancies have been treated by PDT (11). In our institution,
211 patients with central type lung cancers including 66
patients of endoscopically evaluated early-stage lesions
have been treated with PDT since 1980, and a CR rate of
66.7% was achieved for early-stage lesions treated only
withPDT (12). In spite ofthese excellent results, PDT has
not yet been generally been accepted as a standard cancer
therapy, such as radiation orchemotherapy. One ofthe rea-
sons is its side effect, skin photosensitivity. Among pa-
tientswho didnotheedrecommendations to avoid sunlight
and use sunscreens, many (90%) had skin photosensitiv-
ity due to the retention of appreciable amounts of photo-PDT FOR LUNG CANCER WITH BAI 205
Figure 1 Patient 1" A, nodular tumor at the rightB6, 5 by 5 mm in size;
B, shows the same site 2 months after BAI-PDT.
sensitizers in the skin. This skin reaction is potentially so
severe that patients must be warned to avoid exposure to
direct sunlight for several weeks (4).
Preliminary studies in animals suggest that low doses
(0.5 mg/kg) of Photofrin eliminate skin photosensitivity
(13); in addition, Lam et al. (10) indicated that 0.25 mg/kg
of Photofrin is enough to diagnose early-stage lung can-
cer without any skin photosensitivity (10). On the other
hand, the selective infusion yields a higher uptake of drug
in tumor tissues. The platinum concentration in resected
tumor specimens has been reported to be 2 to 4.5 times
higher than in normal tissue, and clinical and histologic
studies have shown a recognizable effect after BAI
(8,14,15). The Seldingermethod is now used for puncture.
Skill and experience should enable the endoscopist to suc-
cessfully perform this even in patients with arteriosclero-
sis and anatomic abnormalities (8,16). Adverse
reactions--intra-arterial infusion, infection and thrombo-
sis around the insertion site of catheters, hemorrhage due
to catheter damage, and intimal damage during insertion
of cathetermmay occur; however, serious complications
such as paralysis were not reported (16). Therefore, to in-
crease the concentration ofdrug in the tumor and decrease
systemic distribution in the rest of the body, it seems log-
ical to infuse the drug directly into the tumor-feeding
bronchial artery.
Unfortunately, the photosensitizer pharmacokinetics
and distribution in man are still unknown (17); however,
an experimental study in dogs revealed that intra-arterial
injection of Photofrin achieved higher Photofrin accumu-
lation than intravenous injection (18). Kostron et al. (19)
reported the effectiveness of PDT with intra-arterial in-
jection of Photofrin for brain tumors.
Lung cancer is a difficult disease to treat curatively be-
cause of its systemic nature, development in older persons,
and multiple primary lesions. Surgery has proved to be the
best curative modality so far. However, in the authors’ in-
stitution, the overall 5-year survival rate is still only 18%
during the past 42 years. As opposed to this, in the early-
stage central-type lung cancer with the tumor invasion of
cm or less, we obtained a 5-year survival rate of 100%
(20). To control the lung cancer death rate, mass surveys
forthe detection ofearly-stage lung cancer, havebeen used
in the elderly with annual chest x-ray and sputum cytol-
ogy for the past 7 years. However, surgical treatment is
limited in older persons, and there is also the problem of
multiple lung cancers in this aged group.
In this study complete remission was obtained in all
patients with minimally invasive lung cancers treated by
BAI-PDT. No evidence of significant skin photosensi-
tivity was obtained in all patients when the low dose of
0.7 mg/kg. Photofrin was given by BAI. These results
may suggest thatBAI-PDT holds promise for clinical ap-
plication. Precise dosimetry yet remains to be estab-
lished, and safe exposure to an unlimited amount of
visible light in the natural environment has not been es-
tablished in patients receiving Photofrin. Lam et al. (10)
suggested that there was a threshold for skin photo-
sensitivity reaction between 0.25 and 2 mg/kg Photofrin;
however, further work on dosemetry remains to be
performed.206 T. OKUNAKA et al.
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